Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Clinical trial NCT06780930 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06780930
Sponsor: Servier
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Residual or Recurrent Grade 2 IDH Mutant Glioma

Start date: 2024-10-18
Primary completion: 2026-05-07
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.